New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Treatment & Care \ Treatment \ Drugs \ Lax101 \ Human
   
LAX 101 : Human Treatment Section
  LAX-101, pure ethyl eicosapentaenoate (EPA), is in trial for the treatment of HD. LAX-101 is manufactured by Laxdale in the UK. Amarin is the distributor in the US. --Jerry 29-Oct-01
 

Amarin Phase III LAX-101 Huntington Trial
Near term focus is to maintain progress with LAX-101 for Huntington's disease. We expect an additional U.S. Phase III clinical ...
Jerry Lampson
Posted to HDL: 25 Mar 2004

LAX-101 Additional Phase 3 Trials
LAX-101 is a novel and proprietary product being developed for treatment of the symptoms of Huntington's Disease (HD). LAX-101 has ...
Jerry Lampson
Posted to HDL: 03 Feb 2003

Amarin Readies LAX-101 Launch
Amarin announced today that it has completed a private placement of 6,093,727 ordinary shares to a group of accredited investors ...
Adapted from Amarin press release by Jerry Lampson
Posted to HDL: 28 Jan 2003

$500,000,000 Market For Huntingtons' Disease Treatment
Fast track approval of LAX-101 for the treatment of Huntington's disease. Market for LAX-100 estimated at $500,000,000 ... ...
Adapted www.marketwatch.com by Jerry Lampson
Posted to HDL: 04 Dec 2002

LAX-101 AND HUNTINGTON'S DISEASE: QUESTIONS AND ANSWERS
Questions and answers about LAX-101, the first statistically significant treatment for Huntington's disease in phase 3 clinical trials. ... ...
Crispin Bennett PhD
Posted to HDL: 04 Nov 2002

LAX-101 Study Results in Huntington's Disease
Amarin Corporation Announces Encouraging Preliminary Results of LAX-101 Pivotal Study in Huntington's Disease ... ...
Crispin Bennett PhD, Research Information Manager, Laxdale Ltd.
Posted to HDL: 28 Oct 2002

**** HD Treatment LAX101 To Be Available
We knew it all along. HD is a treatable condition. LAX101 is expected be available in the first half of ...
From HDL contributor Ron Hartley 17Jun02
Posted to HDL: 17 Jun 2002

****LAX-101 NPL's Breakthrough
LAX-101 and NPLs Demonstrate Benefit in the Treatment of Huntington's Disease in Separate Phase II Studies..Monash study was halted on ...
Amarin Press Release
Posted to HDL: 23 Jan 2002

LAX-101 Presentation
LAX-101, pure ethyl eicosapentaenoate (EPA), is in trial for the treatment of HD. LAX-101 is manufactured by Laxdale in the ...
Rick Stewart, CEO of Amarin, Salomon Smith Barney 2001 Healthcare Conference
Posted to HDL: 21 Sep 2001

LAX-101 Trial, The trial is now up and running
We at Laxdale follow with great interest all that is posted on the HD Lighthouse Website. We thought you would ...
Crispin Bennett, PhD Research Information Manager 30-May-2001
Posted to HDL: 30 May 2001

Show all Updates for this section listed by Date

Read the HDAC/HDLighthouse Forum. Post your comments
   
 
Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org